About

In June 2021, Panavance Therapeutics Inc, a clinical stage biotechnology company focused on novel oncology therapeutics, was incorporated in Delaware. The Company’s lead product candidate, GP-2250, is a novel clinical stage tumor cell selective oncology treatment. Panavance is currently enrolling pancreatic cancer patients from multiple sites in the United States in a phase 1 dose-escalation clinical trial. The company has identified a pathway to registration for a first line pancreatic cancer indication where there are no US FDA approved agents and plans to initiate a pivotal registration trial (in early 2023). GP-2250 is also being explored for other indications such as gynecologic and other tumor types and is currently in preclinical stages for these indications. Prior to its formation in June 2021, the Company was a research and development unit of Geistlich Pharma AG (GPAG).